FDA.reportPublic FDA data

aflibercept-boav 2 MG in 0.05 ML Injection

RxCUI
2725899
RxNorm name
aflibercept-boav 2 MG in 0.05 ML Injection
Display name
aflibercept-boav 2 MG in 0.05 ML Injection
Full name
aflibercept-boav 2 MG in 0.05 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:05

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
7dd4c4da-fe59-4208-927d-7e7965bd7d69aflibercept-boav 2 MG in 0.05 ML Injection [PSN] · 0.05 ML aflibercept-boav 40 MG/ML Injection [SCD] · aflibercept-boav 2 MG per 0.05 ML Injection [SY]34These highlights do not include all the information needed to use EYDENZELT safely and effectively. See full prescribing information for EYDENZELT. EYDENZELT ® (aflibercept-boav) injection, for intravitreal use Initial U.S. Approval: 2025 EYDENZELT ® (aflibercept-boav) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful diff20251017